Stock Ratings / Health Care / NEO / forecast

ULS (69) ADUS (69) TMDX (69) PBH (72) ⌘ Pro Terminal →

NeoGenomics Inc. (NEO) 12-Month Stock Forecast & Price Target Cone

$17.93 -0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

NeoGenomics Inc. (NEO) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEO)Realized 20D OHLCV Swing Band: ±11.9%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NEO Position Size: $10,000

Shares at $17.93: 557.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $13.17

$7,345

$-2,655 (-26.5%)

12M Consensus BaseTarget $16.88

$9,414

$-586 (-5.9%)

12M Bull Case BreakoutTarget $21.16

$11,801

+$1,801 (+18.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$18	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$20	69%	B
JP MorganUS Large-Cap Research	SELL	$15	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEO)

✓Walkthrough of NEO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +93.63%▲ ASCENDING CHANNEL

2026-10-30O $17.95H $18.15L $17.09C $17.93VOL 1.46M

RES: $20.41SUP: $16.15SMA50: $17.68SMA200: $12.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEO Butterfly Map → + Track NEO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEO)

Health Care Rank #471 of 1016 ⚔️ ULS vs NEO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEO vs. ULS, ADUS, TMDX, PBH)

Industry: Precision Instruments (2 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NeoGenomics Inc. (NEO) ranks #471 by composite RQD confidence (45/100, grade D) and #235 by equity capitalization ($2.32B). Within this direct 5-issuer industry benchmark cohort, PBH leads on earnings valuation at 12.1x trailing P/E, while ULS leads on capital efficiency and profitability with 28.3% ROIC and 49.5% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with NEO at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEO ACTIVE NeoGenomics Inc.	D	45/100	—	43.2%	-9.0%	-0.33%	$2.32B	Benchmark Subject
ULS UL Solutions Inc.	C+	69/100	46.9x	49.5%	28.3%	+4.23%	$15.24B	/uls-vs-neo →
ADUS Addus HomeCare Corporation	C+	69/100	24.2x	32.5%	9.1%	+1.77%	$2.32B	/adus-vs-neo →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-neo →
PBH Prestige Consumer Healthcare Inc.	B	72/100	12.1x	54.7%	13.8%	+2.01%	$2.31B	/pbh-vs-neo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001077183

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeoGenomics Inc. (NEO) reported GAAP revenue of $727.3M (+10.1% vs. FY2024 revenue of $660.6M ) , GAAP net income of -$108.0M, operating cash flow of $5.2M, and free cash flow of -$21.8M (+36.0% YoY). On the balance sheet, NEO closed FY2025 with $1.36B in total assets against $341.9M in total debt (Altman Z-Score: 2.72, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$727.3M	-$108.0M	$5.2M	-$21.8M	$1.36B	$341.9M
FY2024 (FY)	2024-12-31	$660.6M	-$79.0M	$7.0M	-$34.0M	$1.64B	$340.3M
FY2023 (FY)	2023-12-31	$0	-$88.0M	-$2.0M	-$2.0M	—	—

3. NEO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NeoGenomics Inc. (NASDAQ: NEO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $17.93 (-0.33% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NEO ranks #471 in composite RQD confidence.

How does NEO compare to ULS and ADUS in the Health Care sector?

Within the Health Care sector (Precision Instruments), NEO carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 43.2%, and ROIC of -9.0%. By comparison, ULS (UL Solutions Inc.) holds a C+ grade (69/100 RQD, P/E 46.9x, ROIC 28.3%, cap $15.24B) and ADUS (Addus HomeCare Corporation) posts a C+ grade (69/100 RQD, P/E 24.2x, ROIC 9.1%, cap $2.32B). Among the 5-stock peer group, PBH leads on earnings multiple (12.1x) while ULS leads on capital efficiency (28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEO?

Per NEO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001077183), NeoGenomics Inc. generated $727.3M in revenue (+10.1% YoY), -$108.0M in net income, and -$21.8M in free cash flow against $1.36B in total assets and $341.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEO trading relative to its 50-day, 200-day, and 52-week technical levels?

NEO last traded at $17.93 (-0.33% on volume of 3,759,052 shares), positioning the stock +1.41% above its 50-day simple moving average ($17.68) and +40.30% above its 200-day simple moving average ($12.78). Across its 52-week range of $7.07 to $20.15, NEO sits at the 83.0% percentile with a 14-day RSI of 51.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($15.80 to $20.06).

NEO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NEO's 12-month stock price target?

NeoGenomics Inc. (NEO) carries a 12-month consensus base price target of $16.88 (-5.9% from $17.93), with a bull-case target of $21.16 and a bear-case floor of $13.17.